Jim Cramer Talked About These 8 Stocks

4. Gilead Sciences, Inc. (NASDAQ:GILD)

Number of Hedge Fund Holders: 59

Cramer said to take profits in Gilead Sciences, Inc. (NASDAQ:GILD) and commented:

“Okay, Gilead Sciences is a company that I think has been, the stock has come back and that’s terrific, but I don’t think the business is worth as much as the stock is selling. I would take profits in that stock tomorrow morning.”

Gilead Sciences (NASDAQ:GILD) is a biopharmaceutical company focused on developing and commercializing innovative medicines. In the third quarter, it reported strong financial results, surpassing analysts’ expectations with a 7% increase in revenue compared to the previous year. This growth was primarily driven by solid sales of its HIV and oncology treatments. The company also made significant progress in its virology and inflammation programs during the quarter.

The company is focused on maintaining its leadership in the HIV treatment market, anticipating the introduction of four new regimens by the end of 2030. Management mentioned that the HIV treatment market is expected to continue growing at a rate of 2 to 3% annually, aligning with the company’s expectations. One key development in the quarter was that the FDA granted breakthrough therapy designation to lenacapavir, an HIV treatment.

If approved, lenacapavir will become the first twice-yearly subcutaneous injection for HIV prevention. The company is on track to file for approval before the end of the year. In addition to its HIV advancements, Gilead Sciences (NASDAQ:GILD) also received FDA-accelerated approval for Livdelzi, a treatment for primary biliary cholangitis, in the third quarter.

This approval brings the total number of innovative therapies launched by Gilead since 2019 to six, marking progress toward the company’s goal of introducing at least 10 transformative therapies by 2030. Furthermore, on December 17, the company announced that the FDA had granted Breakthrough Therapy Designation to Trodelvy for the treatment of extensive-stage small cell lung cancer, further expanding its oncology portfolio.